Medication info

MSPOLMIN Sustained Release Tablets 5/50/750 mg (Empagliflozin, Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›750mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tabletEmpagliflozin L-Proline›6.28mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Purple, oval, double convex, sustained-release film-coated tablets
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202500916 · Approved 2025.04.16

Summary

Main use
Improves blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration. Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily. For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Improves blood glucose control in adults with type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes improve blood glucose control. It is particularly suitable for adult patients who combine diet and exercise therapy, effectively managing blood glucose levels through a combination of three ingredients: empagliflozin, sitagliptin, and metformin. This supports stable maintenance of blood glucose levels and diabetes management.

How to take

Adult dose

For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration. Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily. For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication contains sitagliptin, empagliflozin, and metformin. Firstly, the sitagliptin component can rarely cause serious allergic reactions, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur after taking the medication, it should be discontinued immediately, and a doctor should be consulted. Moreover, sitagliptin can lead to acute pancreatitis, a serious side effect characterized by inflammation of the pancreas, so if symptoms such as abdominal pain, vomiting, or nausea occur, the patient should go to the hospital immediately. The metformin component can rarely cause lactic acidosis, a very dangerous condition, so if symptoms such as shortness of breath, muscle pain, fatigue, abdominal pain, or vomiting occur, the medication should be stopped immediately and emergency treatment sought. This medication should not be used in patients with type 1 diabetes, severely impaired kidney function, severe liver disease, acute heart failure, or serious infections or dehydration. Especially before and after tests using radiocontrast agents, this medication should be temporarily discontinued, and it should be resumed only after confirming normal kidney function post-examination. Elderly patients or those with slightly impaired kidney function should undergo regular kidney function tests, and dosage adjustment or discontinuation may be considered if necessary. This medication has glucose-lowering effects, so caution is needed when taken with insulin or other glucose-lowering agents, as hypoglycemic symptoms may occur. Additionally, this medication can increase the risk of genital infections and urinary tract infections, so prompt treatment should be sought if symptoms of infection arise. Symptoms of low blood pressure and dehydration can also occur due to fluid loss, so caution should be exercised to avoid dehydration from diarrhea or vomiting. If sudden joint pain or blistering skin conditions occur during medication use, a doctor should be informed immediately, and the medication may need to be discontinued if necessary. It is safe not to use this medication during pregnancy or in cases of severe liver dysfunction. While taking this medication, regular blood tests and physical examinations should be performed to monitor for adverse reactions, and if any abnormal symptoms occur, immediate consultation with medical personnel is recommended.

Side effects

  • Hypersensitivity
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • influenza
  • nasopharyngitis
  • anal abscess
  • perforated appendicitis
Show 120 more
  • cervicitis
  • coronavirus infection
  • otitis media
  • periodontitis
  • dental abscess
  • vaginal infection
  • dyspepsia
  • abdominal pain
  • upper abdominal pain
  • diarrhea
  • dry mouth
  • alcoholic gastritis
  • erosive gastritis
  • hematemesis
  • hemorrhoids
  • nausea
  • chest pain
  • weakness
  • fatigue
  • increased blood sugar
  • weight loss
  • increased serum creatine phosphokinase
  • eyelid spasm
  • diabetic retinopathy
  • keratitis
  • vitreous hemorrhage
  • bladder transitional cell carcinoma
  • prostate cancer
  • renal cell carcinoma
  • right angle block
  • left ventricular hypertrophy
  • hyperglycemia
  • hypoglycemia
  • vulvar pruritus
  • diaphoresis
  • dermatitis
  • bile duct obstruction
  • forearm fracture
  • headache
  • insomnia
  • increased urination
  • sleep apnea syndrome
  • removal of artificial fixation device
  • vomiting
  • changes in bowel habits
  • colitis
  • dental caries
  • enteritis
  • Helicobacter infection
  • external ear infection
  • cataract
  • borderline glaucoma
  • endocrinological ocular disease
  • arthralgia
  • lumbar spinal stenosis
  • spinal canal stenosis
  • cough
  • eosinophilic bronchitis
  • oropharyngeal pain
  • contusion
  • foot fracture
  • radiculopathy
  • thalamic infarction
  • breast mass
  • keloid scar
  • rash
  • aneurysm
  • hypotension
  • ventricular extrasystole
  • gill pouch
  • vulvovaginitis
  • balanitis
  • urinary tract infection
  • perineal gangrene
  • constipation
  • taste disorder
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
  • pruritus
  • urticaria
  • severe joint pain with disability
  • vesicular pemphigoid
  • myalgia
  • extremity pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • acute kidney failure
  • upper respiratory tract infection
  • headache
  • severe arthralgia
  • vesicular pemphigoid
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • otalgia
  • positional vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • anxiety
  • depression
  • sleep disorder
  • angina
  • Prinzmetal angina
  • coronary artery disease
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • unstable angina
  • hypertension
  • insomnia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a sealed container. Additionally, it is best to keep it at room temperature between 1°C and 30°C, avoiding extremely hot or cold conditions.

Appearance and packaging

Appearance

Purple, oval, double convex, sustained-release film-coated tablets

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.